SCHEMBL23959556

SCHEMBL23959556

Cc1ccc(OC2CCN(C(=O)Cn3nc(C(=O)N4CCO[C@@H](C)C4)c4c3CCC4)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
KCNH2 Q12809 1/20 0.37
MCHR1 Q99705 1/20 0.37
POLB P06746 1/20 0.37
PIK3CD O00329 1/20 0.36
PIK3R2 O00459 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
PIK3R5 Q8WYR1 1/20 0.36
PIK3R3 Q92569 1/20 0.36
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
IDO1 P14902 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
ALOX15 P16050 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23959626 0.93 KMT2A (0.43) KMT2AKCNH2MCHR1POLBPIK3CD
SCHEMBL23959594 0.93 KMT2A (0.43) KMT2AKCNH2MCHR1PIK3CDPIK3R2
SCHEMBL21752604 0.93 KMT2A (0.52) KMT2AKCNH2MCHR1POLBALOX15
SCHEMBL23959539 0.91 KDM4E (0.41) KMT2AKCNH2MCHR1PIK3CDPIK3R2
SCHEMBL23959560 0.91 LIPE (0.43) KMT2APOLBKDM4ELMNAALOX15
SCHEMBL23959602 0.89 KMT2A (0.40) KMT2APOLBPIK3CDPIK3R2PIK3CA
SCHEMBL23959580 0.87 CNR1 (0.42) KMT2APIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL23959578 0.87 MLNR (0.43) KMT2APIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL21752663 0.85 KMT2A (0.51) KMT2AKCNH2MCHR1KDM4EALOX15
SCHEMBL21752700 0.85 KMT2A (0.51) KMT2AKCNH2MCHR1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210330676-A1 NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210330676-A1 NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS IDO1, IDO2, KYNU KMT2A 1461/4885KCNH2 3856/4885MCHR1 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.